The prediction of early progressive disease in patients with hepatocellular carcinoma receiving atezolizumab plus bevacizumab.
Yasuto TakeuchiKazuhiro NousoShin-Ichi FujiokaKazuya KariyamaHaruhiko KobashiShuji UematsuAkio MoriyaHiroaki HagiharaHiroyuki TakabatakeShinichiro NakamuraKazuhisa YabushitaTatsuya KikuchiAtsushi OyamaTakuya AdachiNozomu WadaHideki OnishiHidenori ShirahaAkinobu TakakiPublished in: Cancer medicine (2023)
The liver function and systemic therapy are useful predictors of e-PD in HCC patients treated with atezolizumab plus bevacizumab in real-world clinical practice.